CA2251972A1 - Combination therapy for reducing the risks associated with cardiovascular disease - Google Patents

Combination therapy for reducing the risks associated with cardiovascular disease Download PDF

Info

Publication number
CA2251972A1
CA2251972A1 CA002251972A CA2251972A CA2251972A1 CA 2251972 A1 CA2251972 A1 CA 2251972A1 CA 002251972 A CA002251972 A CA 002251972A CA 2251972 A CA2251972 A CA 2251972A CA 2251972 A1 CA2251972 A1 CA 2251972A1
Authority
CA
Canada
Prior art keywords
hmg
inhibitor
pharmaceutically acceptable
vitamin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002251972A
Other languages
English (en)
French (fr)
Inventor
Jonathan A. Tobert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9612082.9A external-priority patent/GB9612082D0/en
Priority claimed from GBGB9616804.2A external-priority patent/GB9616804D0/en
Application filed by Individual filed Critical Individual
Publication of CA2251972A1 publication Critical patent/CA2251972A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002251972A 1996-04-17 1997-04-14 Combination therapy for reducing the risks associated with cardiovascular disease Abandoned CA2251972A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US1568996P 1996-04-17 1996-04-17
US60/015,689 1996-04-17
GB9612082.9 1996-06-10
GBGB9612082.9A GB9612082D0 (en) 1996-06-10 1996-06-10 Combination therapy for reducing the risks associated with cardiovascular disease
US2097796P 1996-06-24 1996-06-24
US60/020,977 1996-06-24
GB9616804.2 1996-08-09
GBGB9616804.2A GB9616804D0 (en) 1996-08-09 1996-08-09 Combination therapy for reducing the risks associated with cardiovascular disease

Publications (1)

Publication Number Publication Date
CA2251972A1 true CA2251972A1 (en) 1997-10-23

Family

ID=27451457

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251972A Abandoned CA2251972A1 (en) 1996-04-17 1997-04-14 Combination therapy for reducing the risks associated with cardiovascular disease

Country Status (5)

Country Link
EP (1) EP0904082A4 (de)
JP (1) JP2000508659A (de)
AU (1) AU732465B2 (de)
CA (1) CA2251972A1 (de)
WO (1) WO1997038694A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2265827A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
JP2001517617A (ja) 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
EP1037623A1 (de) * 1997-12-12 2000-09-27 Warner-Lambert Company Hypolipaemische kombinationen aus statin und lp(a)-inhibitoren
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
GB2336534A (en) 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
WO2001076632A1 (en) * 2000-04-10 2001-10-18 Wald Nicholas J Formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
US6916849B2 (en) 2000-10-23 2005-07-12 Sankyo Company, Limited Compositions for improving lipid content in the blood
WO2002034261A1 (fr) * 2000-10-23 2002-05-02 Sankyo Company, Limited Compositions hypocholesterolemiantes
CN1240379C (zh) 2000-11-07 2006-02-08 三共株式会社 过氧化脂质降低剂组合物
JP2004514684A (ja) * 2000-11-29 2004-05-20 スミスクライン・ビーチャム・コーポレイション 心臓血管健康状態の改善のためのスタチンおよびカルシウムを含有する組成物
WO2002047682A1 (fr) * 2000-12-14 2002-06-20 Sankyo Company, Limited Composition ameliorant les lipides sanguins
US7037934B2 (en) 2000-12-14 2006-05-02 Sankyo Company, Limited Blood lipid ameliorant composition
WO2002047683A1 (fr) * 2000-12-14 2002-06-20 Sankyo Company, Limited Composition ameliorant les lipides dans le sang
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
CZ309209B6 (cs) * 2001-01-26 2022-05-25 Schering Corporation Farmaceutický prostředek
WO2004006919A1 (ja) * 2002-07-11 2004-01-22 Sankyo Company, Limited 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
JP4607436B2 (ja) * 2002-08-02 2011-01-05 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
CA2494801A1 (en) * 2002-08-02 2004-02-12 Sankyo Company Limited Medicinal composition containing hmg-coa reductase inhibitor
JP2007515435A (ja) * 2003-12-23 2007-06-14 メディキュア インターナショナル インコーポレイテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤及びビタミンＢ６関連化合物を含む組成物を用いる併用療法
BRPI0509374A (pt) * 2004-03-29 2007-09-11 Wyeth Corp suplementos nutricionais multivitamìnicos e minerais
EP1841436A4 (de) * 2005-01-05 2008-02-20 Medicure Int Inc Verbindungen und verfahren zur regulierung der triglyceridspiegel
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
EP2810644A1 (de) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Orale Formulierung zur Behandlung von Herz-Kreislauf-Erkrankungen
JP6443935B2 (ja) * 2013-07-26 2018-12-26 学校法人 久留米大学 動脈硬化の治療または予防のためのアスピリンおよび葉酸の併用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895107A (en) * 1970-04-15 1975-07-15 Morrison L M CSA and CSC in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
DE4326698C2 (de) * 1993-08-09 1997-05-28 Puetter Medice Chem Pharm Verwendung einer Kombination aus Folsäure, Vitamin B¶6¶ und Vitamin B¶1¶¶2¶ zur Prophylaxe und Therapie von Arteriosklerose
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase

Also Published As

Publication number Publication date
EP0904082A4 (de) 2001-09-26
AU2666597A (en) 1997-11-07
JP2000508659A (ja) 2000-07-11
AU732465B2 (en) 2001-04-26
EP0904082A1 (de) 1999-03-31
WO1997038694A1 (en) 1997-10-23

Similar Documents

Publication Publication Date Title
CA2251972A1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US6673831B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
JP4711600B2 (ja) シトステロール血症の処置のための置換アゼチジノン化合物の使用
ES2342609T3 (es) Agente terapeutico para hiperlipemia que comprende pitavastatinas y acido eicosapentaenoico.
Bermingham et al. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
AU753657B2 (en) Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease
CA2039763A1 (en) Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
EP0373507A1 (de) Zusammensetzung eines HMG-CoA-Reductase-Inhibitors und anderen Serumcholesterol senkenden Mitteln und Verfahren zur Senkung von Serumcholesterol durch diese Zusammensetzung
EP0475148A1 (de) Pravastatin allein oder in Kombination mit einem Fibronsäurederivat zur Vorbeugung des Auftretens oder zur Behandlung von Hyperlipoproteinemia Typ-III
EP1021087A1 (de) Serotonin enthaltende formulierung zur oralen verabreichung und verfahren zurverwendung
WO2001045698A1 (en) Combination therapy for treating neurodegenerative disease
US4559326A (en) Antiinflammatory compositions and methods
JPH0140009B2 (de)
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
US4534974A (en) Pharmaceutical compositions with codeine
RU2266736C2 (ru) Способ и композиции для ингибирования артериосклероза
US20040023919A1 (en) Blood lipid ameliorant composition
CN100566716C (zh) 治疗高血脂症的组合物
WO1998001116A1 (en) Therapy for combined hyperlipidemia
AU6219799A (en) Pharmaceutical combination of ibuprofen-lysine and domperidone for treating migraine
CN100358526C (zh) 治疗高血脂症的组合物
Randinitis et al. Pharmacokinetic profile of a 300‐mg extended phenytoin sodium capsule (Dilantin) formulation
JP2003501385A (ja) Ｈｍｇ−ｃｏａレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ
CN1332657C (zh) 一种含洛伐他汀的组合物及其用途
CN100566717C (zh) 治疗高血脂症的组合物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead